Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells Hanxian ZengSijie LiuPengfei WangXiying QuHaiyan Ji • Xiaohui WangXiaoli ZhuZhishuo SongXinyi YangZhongjun Ma •

Huanzhang Zhu
2014-01-01
Abstract:The long-lived latently infected cells persist in spite of prolonged highly active anti-retroviral therapy and present a major barrier to a cure of human immunodefi- ciency virus type 1 (HIV-1) infection. Elimination of this reservoir requires reactivation of the latent virus. None of the current agents can safely and effectively reactivate latent HIV-1 reservoirs. Dilazep, a nucleoside transport inhibitor, is used to treat ischemic dysfunction. However, little is known about the effect of dilazep in inducing HIV expression in latently infected cells. Using the Jurkat T cell model of HIV-1 latency, we found that dilazep effectively reactivates latent HIV-1 gene expression in a dose manner. We observed that dilazep synergistically reactivated latent HIV-1 transcription with valproic acid. We also found that dilazep activates viral latency without inducing cell surface activation markers CD25 and CD69 activation. In sum- mary, dilazep, alone or in combination with VPA, could be useful in future eradication strategies.
What problem does this paper attempt to address?